{"disease":{"id":"molecular-targeted-therapy","name":"molecular targeted therapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04521153","title":"Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":294,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT04586088","title":"Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":58,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04642547","title":"Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT06848439","title":"Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":26,"lead_sponsor_name":"Jiangsu Cancer Institute & Hospital","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}